Ampio Pharmaceuticals (OTC: AMPE)
Ampio Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ampio Pharmaceuticals Company Info
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
News & Analysis
Here's Why Ampio Pharmaceuticals Stock Is Surging Today
A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.
Why Ampio Pharmaceuticals Stock Is Jumping Today
Investors liked what they heard in the company's Q4 update.
Why Ampio Pharmaceuticals Stock Tanked Today
Investors weren't comfortable with FDA feedback on the company's late-stage clinical trial.
Here's Why Ampio Pharmaceuticals Inc. Became a Penny Stock Today
The company's lead drug candidate just received some bad news from the FDA.
Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today
What goes up must come down.
Here's Why Ampio Pharmaceuticals Sank as Much as 13.5% Today
An important industry analyst has little hope for the tiny company.
Why Ampio Pharmaceuticals Rose as Much as 15% Today
The small-cap biopharma stock has exploded at the end of 2017.
5 of Last Week's Biggest Winners
These five stocks posted double-digit percentage gains.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2025.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.